Trial Profile
A phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with or without docetaxel in adult patients with advanced solid tumors or lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2011
Price :
$35
*
At a glance
- Drugs EZN 3042 (Primary) ; Docetaxel
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 12 Nov 2011 Results from patients with advanced solid tumours presented at the AACR-NCI-EORTC 2011.
- 05 Apr 2011 Results presented at AACR 2011.
- 05 Apr 2011 Status changed from recruiting to completed.